Mirum Pharmaceuticals (MIRM)
Commercializes rare-disease medicines while building a broader liver and genetic-disease pipeline.
Something off on this page? Send us feedback.
Sells LIVMARLI, CHOLBAM, and CTEXLI for rare liver and genetic disorders while developing medicines for additional cholestatic, viral, skeletal, and neurocognitive diseases. LIVMARLI generates most product revenue, U.S. sales dominate the mix, and manufacturing is fully outsourced.
Commercializes three rare-disease medicines: LIVMARLI for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM for bile-acid synthesis and peroxisomal disorders, and CTEXLI for cerebrotendinous xanthomatosis. Revenue comes from product sales, with LIVMARLI contributing most and the United States accounting for most sales.
Builds on a focused specialty-commercial model in North America and parts of Europe, using distributors and licensees elsewhere. Development programs span additional LIVMARLI uses, volixibat for adult cholestatic liver disease, brelovitug for chronic hepatitis delta, zilurgisertib for fibrodysplasia ossificans progressiva, and MRM-3379 for Fragile X syndrome.
Regulatory approvals and reimbursement govern access, while all manufacturing is outsourced to contract producers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 27, 2026 | UBS | Target | Target: $140 | Target: $137 |
| Aug 6, 2026 | Robert W. Baird | Target | Target: $129 | Target: $123 |
| Aug 6, 2026 | Morgan Stanley | Target | Target: $150 | Target: $137 |
| Aug 6, 2026 | RBC Capital | Reiterate | Rating: —Target: $148 | Target: $135 |
| Aug 6, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $185 | Target: $140 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $438.3M · Total debt $760.5M · Total assets $1.04B · Shareholders' equity −$10.4M
- Revenue
- $176.2M
- Operating income
- −$42.5M
- Net income
- −$67.2M
No dividends on record.
| Institutions | 110.70% | 71.88M shares | |
|---|---|---|---|
| 338 holders · as of Jun 30, 2026 | |||
| Insiders | 8.18% | 5.31M shares | |
| 14 holders · as of Sep 22, 2026 | |||
| Adds to | 118.88% | ||
64.93M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 118.88%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Frazier Life Sciences Management, L.P.Institution | 11.83% | 7.68M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 9.10% | 5.91M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.76% | 4.39M | as of Jun 30, 2026 |
Life Sciences IX L.P. FrazierInsider10 percent owner | 6.33% | 4.11M | filed Jan 27, 2026 |
FMR LLCInstitution | 5.65% | 3.67M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Eric Bjerkholt | officer: CHIEF FINANCIAL OFFICER | −9,943 | $98.37 |
| Sep 1, 2026 | Christopher Peetz | director, officer: CHIEF EXECUTIVE OFFICER | −30,000 | $98.68 |
| Sep 2, 2026 | Jolanda Howe | officer: SVP, GLOBAL CONTROLLER | −658 | $100.00 |
| Aug 18, 2026 | Jolanda Howe | officer: SVP, GLOBAL CONTROLLER | −40,000 | $100.00 |
| Aug 11, 2026 | Eric Bjerkholt | officer: CHIEF FINANCIAL OFFICER | −6,001 | $99.90 |
- Gilead Sciences
Approved HDV and PBC franchises across liver expansion
- VirBio
Late-stage HDV pipeline pressure on brelovitug
- GSK (ADR)
PBC itch IBAT overlap through Lynavoy/linerixibat
- Regeneron
Near-term FOP regulatory competitor to zilurgisertib
- Pliant Therapeutics
PSC pipeline peer with disease-modifying fibrosis approach
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals | $88.97 | −2.64% | $5.57B | — | — | 9.0 | +37.9% |
| Gilead Sciences | $150.93 | −1.14% | $189.30B | — | 16.7 | 6.2 | +10.2% |
| VirBio | $10.96 | −4.70% | $1.94B | — | — | 6.4 | +19,582.5% |
| GSK (ADR) | $49.97 | −1.48% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Regeneron | $792.80 | −1.38% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| Pliant Therapeutics | $1.11 | −3.07% | $70.6M | — | — | — | — |
| Median | 18.0 | 13.1 | 5.8 | +13.5% |